# Psychological distress in women with breast and gynecological cancer treated with radical surgery

Paloma Gómez-Campelo<sup>1</sup>\*, Carmen Bragado-Álvarez<sup>2</sup> and Maria José Hernández-Lloreda<sup>2</sup>

\*Correspondence to: Fundación de Investigación Biomé dica, Hospital Carlos III, CI Sinesio Delgado, 10. 28029, Madrid, Spain. E-mail: pgomezc@salud.madrid.

#### **Abstract**

*Objectives*: The objective of this study is to compare psychological distress (body image disturbance, self-esteem, depression, and anxiety) in women with breast or gynecological cancer treated by radical surgery. Additionally, another objective is to analyze the association between psychological distress and sociodemographic characteristics, medical history, and social support to produce a prediction model for the outcome measures.

Methods: A cross-sectional study was carried out with 100 women who had undergone radical surgery for breast or gynecological cancer. Both groups were divided into the following: younger than 50 years old and 50 years old or older. Body Image Scale, Rosenberg's Self-Esteem Scale, Beck Depression Inventory, and Beck Anxiety Inventory were used.

Results: Age had a significant main effect on psychological distress but the type of cancer did not. Younger women showed significantly greater distress than older women (p-values < 0.001). A significant interaction between age and type of cancer was found, indicating that older women with breast cancer had worse body image and more depression than those with gynecological cancer (p-values 0.001); no significant differences were found between younger groups.

The prediction model for increased body image disturbance and depression included the joint effect of the following variables: being younger, inactive occupational status, and post-adjuvant therapy side effects. For lower self-esteem, the variables were: being younger, post-adjuvant therapy side effects, and dissatisfaction with social support. And for higher anxiety, the sole variable included was post-adjuvant therapy side effects.

Conclusions: Both mastectomy and hysterectomy/oophorectomy cause similar psychological distress in younger women, but mastectomy causes greater distress in older women than hysterectomy/oophorectomy.

Copyright © 2013 John Wiley & Sons, Ltd.

Received: 21 December 2012 Revised: 19 September 2013 Accepted: 3 October 2013

# **Background**

Breast cancer (BC) and gynecological cancer (GC) are two of the most commonly diagnosed cancers in women worldwide [1]. In western countries, cancer survival rates have increased over the past 25 years as a result of early detection and more effective treatments [1–4]. However, survival is not synonymous with quality of life and welfare, and many survivors experience significant psychological distress (PD) for years, as a consequence of the disease and its treatments [5–8].

To date, research into distress due to cancers affecting women has primarily focused on BC [9], concluding that mastectomy may cause greater depression/anxiety [10,11], more body image disturbance (BID) [12–16], and lower self-esteem [17,18] than breast-conserving surgery. Comparatively, GC has received much less attention [19], despite the high proportion of hysterectomy/oophorectomy patients reporting severe emotional symptoms [20–22].

Consequently, it is of interest to explore which condition causes greater PD among women, especially

as the loss of any of these organs means the partial loss of female identity.

However, there is still scant information about differential effects of radical surgery in women with BC or GC. The few published studies suggest that mastectomy patients have more depression than hysterectomy patients [8,23], whereas hysterectomy patients have more sexual and relationship problems than mastectomy patients; BID seems to affect both groups equally [8]. Furthermore, research suggests that age may be particularly relevant in PD, showing that younger women (under 50 years old) tend to have better physical functioning than older women but worse emotional well-being and quality of life [24–30].

This paper seeks to provide new data in this scenario, comparing PD (BID, self-esteem, depression, and anxiety) among women with BC and women with GC, both treated with radical surgery, considering the influence of age (younger than 50 vs. 50 years old or older). This cutoff point has been widely used, possibly as most cancers occur in those aged around 50 years or older [3,4,30] and enables researchers to form groups to compare

<sup>&</sup>lt;sup>1</sup>Fundación de Investigación Biomédica, Hospital Carlos III, Madrid, Spain

<sup>&</sup>lt;sup>2</sup>Facultad de Psicología, Universidad Complutense de Madrid, Madrid, Spain

younger (proxy premenopausal) and older (broadly postmenopausal) women [25,31–33]. Furthermore, we analyzed possible associations between sociodemographic characteristics, medical history, and social support with PD. Finally, we conducted a multiple regression analysis to produce a good predictive model for the outcome measures.

Mastectomy and hysterectomy/oophorectomy are very stressful events for women, as they involve the loss of body parts associated with womanhood and femininity, causing significant changes in women's bodies. This generates a large discrepancy between body image (BI) before disease, ideal standards, and the new corporality, therefore questioning the woman's gendered identity [8,34,35]. Regarding their post-surgery body, most experience feelings of mutilation, strangeness, loss of physical and sexual attractiveness, BI concerns, and emotional distress [35,36].

Physical attractiveness is highly valued in western societies, where sociocultural norms of ideal bodies are imposed [37,38]. Therefore, we expected mastectomy women to experience more PD than hysterectomy/oophorectomy women, as the loss of a breast/breasts is an obvious daily reminder of their appearance and disease.

According to previous studies [37–41], we also expected to see more PD among younger than among older women regardless of the type of cancer or surgery. It is likely that the loss of reproductive organs or breasts has a larger impact on younger than among older women as it affects directly their potential life plans. Additionally, research shows that the importance of body appearance tends to decrease with increasing age [42].

# **Methods**

# **Participants**

A cross-sectional study was carried out in the Regional Cancer Center, University General Hospital 'Gregorio Marañón' (Madrid, Spain) with 100 women (aged 18–83 years), who had undergone radical surgery for BC or GC.

Eligibility criteria included the following: women over 18 years old with a confirmed diagnosis of primary BC or GC (endometrium, cervix, or ovarian), stages TI–T3; had undergone mastectomy or hysterectomy/oophorectomy, respectively; were on no current cancer therapy other than hormone therapy; had finished adjuvant treatment 24 months (maximum) prior to the study; had menopause (by age or secondary to treatment), and signed informed consent. Exclusion criteria were the following: not born in Spain, stage T4, had a previous diagnosis of primary cancer in a different location, and suffering severe chronic diseases or significant physical/cognitive disabilities that might invalidate informed consent or interview outcomes.

The patients were consecutively selected and distributed into the following groups: 'BC group', 50 patients with BC treated by mastectomy, divided into 'younger' (younger than 50 years old; n=29) and 'older' (50 years old or older; n=21); and 'GC group', 50 patients with GC treated by hysterectomy/oophorectomy, also divided into 'younger' (n=28) and 'older' (n=22).

#### Measures

Body image disturbance was evaluated using the Body Image Scale (BIS) [43], a 10-item instrument that assesses concerns about BI in cancer patients. BIS has four response options, with a total score ranging 0–30 points, with higher scores meaning greater concerns.

To our knowledge, BIS had not been translated and adapted to Spanish; so, we proceeded with a back-translation technique by two English-speaking natives. Both translations were reviewed by an expert panel and merged into a single version. A pilot test was conducted on a reduced sample of patients (excluded from study) to assess comprehension of the translation, together with a brief questionnaire to ascertain the difficulties encountered. The scale was adapted, and the final version was used; Cronbach's Alpha was 0.96.

Self-esteem was evaluated with the Spanish version of the Rosenberg's Self-Esteem Scale [44,45]. Rosenberg's Self-Esteem Scale comprises a 10-item with a four-point intensity scale, with a total score ranging 0–40 points. Higher scores indicate better self-esteem. Cronbach's Alpha was 0.96.

Depression and anxiety were assessed with the Spanish version of the Beck Depression Inventory [46–48] and the Beck Anxiety Inventory [49,50], respectively. Both instruments consist of 21 items, and each of these rates on a four-point intensity scale; total score ranges 0–63 points. Higher scores reflect more severe depression or anxiety. Cronbach's Alpha was 0.96 and 0.92, respectively.

Sociodemographic data were obtained through an ad hoc questionnaire to ascertain the following: age, marital status (with/without a partner), children (number and plans of having more), education (years), occupation [managerial/professional (professional, technical personnel, executive, or manager); intermediate professions (staff of administrative services, own account workers, etc.); housemaids, homemakers], occupational status (active: employed; inactive: unemployed, retired), and socioeconomic status (self-ranking measure on a 3-point Likert scale: low-medium—high).

Medical information was obtained from the participants and completed with medical records, including the following: type of cancer, surgery, disease stage, time since diagnosis, antineoplastic treatment history, breast reconstruction, post-adjuvant therapy side effects, menopausal complaints, and disease recurrence.

Social support was measured through two questions: 'How much support do you feel you have received from the people around you (family, friends, coworkers, and others) during your disease? (ranging 0-10)', and 'do you feel satisfied with the social support received during your oncological process? (yes/no)'.

#### Procedure

Potential participants were approached by oncologists during routine hospital checkups and invited to participate. Women who agreed to take part in the study were referred to the first author for assessment. Before evaluation, the researcher presented the study, answered the participant's questions, and presented the consent form for signature. The average time spent on administration was 30–45 min. Patients were recruited consecutively until the sample size was sufficient for each group. Data collection was conducted between September 2005 and January 2007.

All patients provided an informed consent according to the hospital ethic guidelines. Research protocol followed ethical standards as outlined in the Helsinki Declaration.

# Statistical analysis

Descriptive analysis was performed for each of the variables studied. Quantitative variables were analyzed using twoway analysis of variance with 'type of cancer' (BC/GC) and 'age' (younger/older) as factors, and PD measures as dependent variables. We tested for assumptions of normality and homogeneity of variances; if they were not satisfied, we performed the Kruskal–Wallis test with post hoc calculations. Qualitative variables were analyzed using Pearson's Chi-square test and Cramer's V. Effect size using Cohen's d was calculated for the outcome variables and significant differences.

Correlation analyses were conducted among sociodemographic, medical and social support variables, and PD measures, and also between the PD measures. Subsequently, a multiple regression analysis using the Enter method was performed to evaluate the joint influence of independent variables (sociodemographic, medical history, and social support) on each PD variable. Variables significantly associated with outcome measures in the correlation analysis were entered in the multiple regression analysis.

Statistical significance was set at p-value < 0.05. Statistical processing of the data was performed with SPSS software (version 19.0, SPSS Inc., Chicago, Illinois) [51].

### Results

## Descriptive data

Patient characteristics are shown in Table 1. The mean age of participants was 48.59 years (SD = 13.79). There

Table I. Sample characteristics

Age Global sample		Breast cancer	Gynecological cancer
Global sample Younger (<50 years) 39.41 (6.49), 27–49 37.79 (7.32), 19–48 Older (≥50 years) 60.71 (9.81), 50–83 62.86 (6.96), 50–75 Marital status (%) Without partner 38 34 Children (number) 1.80 (1.62) 1.66 (1.52) Planning more 65.5 (younger) 50 (younger) children (no) (%) Education (years) 13.06 (6.23) 14.20 (6.52) Occupation (%) Managerial/professional 18 24 Intermediate professions 46 42 Housemaids 4 Indusemakers 32 24 Occupational status (%) Active 30 34 Socioeconomic status (%) Low 52 42 Medium 32 36 High 16 22 Disease stage (%) T1 52 32 32 T2 48 73 20 20 Time since diagnosis (months) Antineoplastic treatment (%) One treatment Three treatment 46 56 Three treatment Three treatment 12 40 Three treatment Three treatment 12 40 Three treatment Menopausal complaints 3.54 (3.25) 4.24 (2.50) Disease recurrence (yes) (%) 20 22 Social support (amount) 5.13 (2.57) 6.33 (2.14) Satisfaction social		(n = 50)	(n=50)
Younger (<50 years) Older (≥50 years) Older (≥50 years) Older (≥50 years) Marital status (%) Without partner 38 38 34 Children (number) I.80 (I.62) Planning more children (no) (%) Education (years) Occupation (%) Managerial/professional Intermediate professions Housemakers Housemakers Active 30 34 Socioeconomic status (%) Low Socioeconomic status (%) Light 16 Disease stage (%) T1 52 T2 T2 T3 T3 20 Time since diagnosis (months) Antineoplastic treatment Two treatment Two treatment Three treatment Three treatment Three treatment Time status (managerial/professions) Post-adjuvant therapy Menopausal complaints Disease recurrence (yes) (%) Satisfaction social Satisfaction social Satia (9.11, 29.4) 13.06 (6.23) 14.20 (6.52) 14.20	Age		
Younger (<50 years) Older (≥50 years) Older (≥50 years) Older (≥50 years) Marital status (%) Without partner 38 38 34 Children (number) I.80 (I.62) Planning more 65.5 (younger) Cocupation (%) Education (years) Occupation (%) Managerial/professional Intermediate professions Housemakers Active 30 34 Socioeconomic status (%) Low 52 Medium 16 High 16 22 Disease stage (%) T1 52 T2 T2 T2 T3 T3 20 Time since diagnosis (months) Antineoplastic treatment Two treatment Two treatment Three treatment	•	48.36 (13.27), 27–83	48.82 (14.43), 19-75
Older (≥50 years)       60.71 (9.81), 50–83       62.86 (6.96), 50–75         Marital status (%)       Without partner       38       34         Children (number)       1.80 (1.62)       1.66 (1.52)         Planning more       65.5 (younger)       50 (younger)         children (no) (%)       50 (younger)         Education (years)       13.06 (6.23)       14.20 (6.52)         Occupation (%)       18       24         Intermediate professional Intermediate professions Ade	· ·	, ,	
Marital status (%)       Without partner       38       34         Children (number)       1.80 (1.62)       1.66 (1.52)         Planning more       65.5 (younger)       50 (younger)         children (no) (%)       50 (younger)         Education (years)       13.06 (6.23)       14.20 (6.52)         Occupation (%)       18       24         Managerial/professional       18       24         Intermediate professions       46       42         Housemaids       4       10         Housemakers       32       24         Occupational status (%)       30       34         Active       30       34         Socioeconomic status (%)       4       10         Low       52       42         Medium       32       36         High       16       22         Disease stage (%)       71       52       32         T2       28       48         T3       20       20         Time since diagnosis (months)       15.64 (7.97)       14.44 (7.91)         Antineoplastic treatment       46       56         Two treatment       42       40         Three treatment </td <td>. , ,</td> <td></td> <td></td>	. , ,		
Without partner         38         34           Children (number)         1.80 (1.62)         1.66 (1.52)           Planning more         65.5 (younger)         50 (younger)           children (no) (%)         50 (younger)           Education (years)         13.06 (6.23)         14.20 (6.52)           Occupation (%)         18         24           Managerial/professional         18         24           Intermediate professions         46         42           Housemaids         4         10           Housemakers         32         24           Occupational status (%)         30         34           Socioeconomic status (%)         30         34           Low         52         42           Medium         32         36           High         16         22           Disease stage (%)         71         52         32           T2         28         48           T3         20         20           Time since diagnosis (months)         15.64 (7.97)         14.44 (7.91)           Antineoplastic treatment         46         56           Two treatment         42         40           Three tre	Marital status (%)	, ,	, ,
Planning more       65.5 (younger)       50 (younger)         children (no) (%)       Education (years)       13.06 (6.23)       14.20 (6.52)         Occupation (%)       Italian (6.23)       14.20 (6.52)         Managerial/professional Intermediate professions Ade	1 /	38	34
children (no) (%)       Education (years)       13.06 (6.23)       14.20 (6.52)         Occupation (%)       Managerial/professional       18       24         Intermediate professions       46       42         Housemaids       4       10         Housemakers       32       24         Occupational status (%)       30       34         Socioeconomic status (%)       30       34         Low       52       42         Medium       32       36         High       16       22         Disease stage (%)       71       52       32         T2       28       48       32         T3       20       20       20         Time since diagnosis (months)       15.64 (7.97)       14.44 (7.91)         Antineoplastic treatment (%)       00       20         One treatment       46       56         Two treatment       42       40         Three treatment       12       4         Side effects       2.94 (2.46)       2.94 (1.93)         post-adjuvant therapy       Menopausal complaints       3.54 (3.25)       4.24 (2.50)         Disease recurrence (yes) (%)       20       22	Children (number)	1.80 (1.62)	1.66 (1.52)
children (no) (%)       Education (years)       13.06 (6.23)       14.20 (6.52)         Occupation (%)       Image: Intermediate professional lisus and line professions line professions and line professions are professions and line professions and line professions are professions are professions and line professions are professions are professions are professional professions are professional professio	Planning more	65.5 (younger)	50 (younger)
Education (years)       13.06 (6.23)       14.20 (6.52)         Occupation (%)       Image: Intermediate professional list and line professions	•	0 0 /	0 0 /
Occupation (%)         Is         24           Managerial/professional         18         24           Intermediate professions         46         42           Housemaids         4         10           Housemakers         32         24           Occupational status (%)         30         34           Socioeconomic status (%)         30         34           Low         52         42           Medium         32         36           High         16         22           Disease stage (%)         71         52         32           T2         28         48         32           T3         20         20         20           Time since diagnosis (months)         15.64 (7.97)         14.44 (7.91)           Antineoplastic treatment (%)         0ne treatment         46         56           Two treatment         42         40         4           Three treatment         12         4         4           Side effects         2.94 (2.46)         2.94 (1.93)         post-adjuvant therapy           Menopausal complaints         3.54 (3.25)         4.24 (2.50)         Disease recurrence (yes) (%)         20         22	. , . ,	13.06 (6.23)	14.20 (6.52)
Managerial/professional         18         24           Intermediate professions         46         42           Housemaids         4         10           Housemakers         32         24           Occupational status (%)         30         34           Socioeconomic status (%)         30         34           Low         52         42           Medium         32         36           High         16         22           Disease stage (%)         71         52         32           T2         28         48         48           T3         20         20           Time since diagnosis (months)         15.64 (7.97)         14.44 (7.91)           Antineoplastic treatment (%)         0ne treatment         46         56           Two treatment         42         40           Three treatment         12         4           Side effects         2.94 (2.46)         2.94 (1.93)           post-adjuvant therapy           Menopausal complaints         3.54 (3.25)         4.24 (2.50)           Disease recurrence (yes) (%)         20         22           Social support (amount)         5.13 (2.57)         6.33 (2.14)<	0 ,	,	,
Intermediate professions         46         42           Housemaids         4         10           Housemakers         32         24           Occupational status (%)         30         34           Socioeconomic status (%)         30         34           Low         52         42           Medium         32         36           High         16         22           Disease stage (%)         71         52         32           T2         28         48         73           T3         20         20           Time since diagnosis (months)         15.64 (7.97)         14.44 (7.91)           Antineoplastic treatment (%)         0ne treatment         46         56           Two treatment         42         40           Three treatment         12         4           Side effects         2.94 (2.46)         2.94 (1.93)           post-adjuvant therapy           Menopausal complaints         3.54 (3.25)         4.24 (2.50)           Disease recurrence (yes) (%)         20         22           Social support (amount)         5.13 (2.57)         6.33 (2.14)           Satisfaction social         76         70	,	18	24
Housemakers       32       24         Occupational status (%)       30       34         Socioeconomic status (%)       52       42         Low       52       42         Medium       32       36         High       16       22         Disease stage (%)       52       32         T1       52       32         T2       28       48         T3       20       20         Time since diagnosis (months)       15.64 (7.97)       14.44 (7.91)         Antineoplastic treatment (%)       0ne treatment       46       56         Two treatment       42       40         Three treatment       12       4         Side effects       2.94 (2.46)       2.94 (1.93)         post-adjuvant therapy         Menopausal complaints       3.54 (3.25)       4.24 (2.50)         Disease recurrence (yes) (%)       20       22         Social support (amount)       5.13 (2.57)       6.33 (2.14)         Satisfaction social       76       70		46	42
Occupational status (%)       30       34         Active       30       34         Socioeconomic status (%)           Low       52       42         Medium       32       36         High       16       22         Disease stage (%)           TI       52       32         T2       28       48         T3       20       20         Time since diagnosis (months)       15.64 (7.97)       14.44 (7.91)         Antineoplastic treatment (%)           One treatment       46       56         Two treatment       42       40         Three treatment       12       4         Side effects       2.94 (2.46)       2.94 (1.93)         post-adjuvant therapy         Menopausal complaints       3.54 (3.25)       4.24 (2.50)         Disease recurrence (yes) (%)       20       22         Social support (amount)       5.13 (2.57)       6.33 (2.14)         Satisfaction social       76       70	Housemaids	4	10
Active       30       34         Socioeconomic status (%)	Housemakers	32	24
Active       30       34         Socioeconomic status (%)	Occupational status (%)		
Low     52     42       Medium     32     36       High     16     22       Disease stage (%)     32     32       T1     52     32       T2     28     48       T3     20     20       Time since diagnosis (months)     15.64 (7.97)     14.44 (7.91)       Antineoplastic treatment (%)     0ne treatment     46     56       Two treatment     42     40       Three treatment     12     4       Side effects     2.94 (2.46)     2.94 (1.93)       post-adjuvant therapy       Menopausal complaints     3.54 (3.25)     4.24 (2.50)       Disease recurrence (yes) (%)     20     22       Social support (amount)     5.13 (2.57)     6.33 (2.14)       Satisfaction social     76     70		30	34
Low     52     42       Medium     32     36       High     16     22       Disease stage (%)     32     32       T1     52     32       T2     28     48       T3     20     20       Time since diagnosis (months)     15.64 (7.97)     14.44 (7.91)       Antineoplastic treatment (%)     0ne treatment     46     56       Two treatment     42     40       Three treatment     12     4       Side effects     2.94 (2.46)     2.94 (1.93)       post-adjuvant therapy       Menopausal complaints     3.54 (3.25)     4.24 (2.50)       Disease recurrence (yes) (%)     20     22       Social support (amount)     5.13 (2.57)     6.33 (2.14)       Satisfaction social     76     70	Socioeconomic status (%)		
High       16       22         Disease stage (%)       32         TI       52       32         T2       28       48         T3       20       20         Time since diagnosis (months)       15.64 (7.97)       14.44 (7.91)         Antineoplastic treatment (%)       0ne treatment       46       56         Two treatment       42       40         Three treatment       12       4         Side effects       2.94 (2.46)       2.94 (1.93)         post-adjuvant therapy         Menopausal complaints       3.54 (3.25)       4.24 (2.50)         Disease recurrence (yes) (%)       20       22         Social support (amount)       5.13 (2.57)       6.33 (2.14)         Satisfaction social       76       70		52	42
Disease stage (%)  TI 52 32  T2 28 48  T3 20 20  Time since diagnosis (months) 15.64 (7.97) 14.44 (7.91)  Antineoplastic treatment (%)  One treatment 46 56  Two treatment 42 40  Three treatment 12 4  Side effects 2.94 (2.46) 2.94 (1.93)  post-adjuvant therapy  Menopausal complaints 3.54 (3.25) 4.24 (2.50)  Disease recurrence (yes) (%) 20 22  Social support (amount) 5.13 (2.57) 6.33 (2.14)  Satisfaction social 76 70	Medium	32	36
Disease stage (%)       TI       52       32         T2       28       48         T3       20       20         Time since diagnosis (months)       15.64 (7.97)       14.44 (7.91)         Antineoplastic treatment (%)       46       56         Two treatment       42       40         Three treatment       12       4         Side effects       2.94 (2.46)       2.94 (1.93)         post-adjuvant therapy         Menopausal complaints       3.54 (3.25)       4.24 (2.50)         Disease recurrence (yes) (%)       20       22         Social support (amount)       5.13 (2.57)       6.33 (2.14)         Satisfaction social       76       70	High	16	22
T2     28     48       T3     20     20       Time since diagnosis (months)     15.64 (7.97)     14.44 (7.91)       Antineoplastic treatment (%)     15.64 (7.97)     14.44 (7.91)       One treatment     46     56       Two treatment     42     40       Three treatment     12     4       Side effects     2.94 (2.46)     2.94 (1.93)       post-adjuvant therapy       Menopausal complaints     3.54 (3.25)     4.24 (2.50)       Disease recurrence (yes) (%)     20     22       Social support (amount)     5.13 (2.57)     6.33 (2.14)       Satisfaction social     76     70			
T3         20         20           Time since diagnosis (months)         15.64 (7.97)         14.44 (7.91)           Antineoplastic treatment (%)         15.64 (7.97)         14.44 (7.91)           One treatment (%)         46         56           Two treatment (42)         40         40           Three treatment (12)         4         42           Side effects (2.94 (2.46))         2.94 (1.93)         2.94 (1.93)           post-adjuvant therapy         Menopausal complaints (3.54 (3.25))         4.24 (2.50)           Disease recurrence (yes) (%)         20         22           Social support (amount) (5.13 (2.57))         6.33 (2.14)           Satisfaction social (76)         70	• . ,	52	32
Time since diagnosis (months)  Antineoplastic treatment (%)  One treatment  46  Two treatment  42  40  Three treatment  12  4  Side effects  2.94 (2.46)  post-adjuvant therapy  Menopausal complaints  3.54 (3.25)  Disease recurrence (yes) (%)  20  22  Social support (amount)  Satisfaction social  15.64 (7.97)  14.44 (7.91)  4  40  2.94 (1.93)  2.94 (1.93)  2.94 (2.50)  6.33 (2.14)  76	T2	28	48
Antineoplastic treatment (%) One treatment 46 56 Two treatment 42 40 Three treatment 12 4 Side effects 2.94 (2.46) 2.94 (1.93) post-adjuvant therapy  Menopausal complaints 3.54 (3.25) Disease recurrence (yes) (%) 20 22 Social support (amount) 5.13 (2.57) 6.33 (2.14) Satisfaction social	T3	20	20
Antineoplastic treatment (%) One treatment 46 56 Two treatment 42 40 Three treatment 12 4 Side effects 2.94 (2.46) 2.94 (1.93) post-adjuvant therapy  Menopausal complaints 3.54 (3.25) Disease recurrence (yes) (%) 20 22 Social support (amount) 5.13 (2.57) 6.33 (2.14) Satisfaction social	Time since diagnosis (months)	15.64 (7.97)	14.44 (7.91)
One treatment         46         56           Two treatment         42         40           Three treatment         12         4           Side effects         2.94 (2.46)         2.94 (1.93)           post-adjuvant therapy         Menopausal complaints         3.54 (3.25)         4.24 (2.50)           Disease recurrence (yes) (%)         20         22           Social support (amount)         5.13 (2.57)         6.33 (2.14)           Satisfaction social         76         70	. ,	,	,
Three treatment         12         4           Side effects         2.94 (2.46)         2.94 (1.93)           post-adjuvant therapy             Menopausal complaints         3.54 (3.25)         4.24 (2.50)           Disease recurrence (yes) (%)         20         22           Social support (amount)         5.13 (2.57)         6.33 (2.14)           Satisfaction social         76         70		46	56
Side effects       2.94 (2.46)       2.94 (1.93)         post-adjuvant therapy       Menopausal complaints       3.54 (3.25)       4.24 (2.50)         Disease recurrence (yes) (%)       20       22         Social support (amount)       5.13 (2.57)       6.33 (2.14)         Satisfaction social       76       70	Two treatment	42	40
post-adjuvant therapy  Menopausal complaints 3.54 (3.25) 4.24 (2.50)  Disease recurrence (yes) (%) 20 22  Social support (amount) 5.13 (2.57) 6.33 (2.14)  Satisfaction social 76 70	Three treatment	12	4
post-adjuvant therapy         3.54 (3.25)         4.24 (2.50)           Menopausal complaints         3.54 (3.25)         4.24 (2.50)           Disease recurrence (yes) (%)         20         22           Social support (amount)         5.13 (2.57)         6.33 (2.14)           Satisfaction social         76         70	Side effects	2.94 (2.46)	2.94 (1.93)
Menopausal complaints       3.54 (3.25)       4.24 (2.50)         Disease recurrence (yes) (%)       20       22         Social support (amount)       5.13 (2.57)       6.33 (2.14)         Satisfaction social       76       70	post-adjuvant therapy	, ,	,
Disease recurrence (yes) (%)         20         22           Social support (amount)         5.13 (2.57)         6.33 (2.14)           Satisfaction social         76         70		3.54 (3.25)	4.24 (2.50)
Social support (amount)         5.13 (2.57)         6.33 (2.14)           Satisfaction social         76         70		, ,	, ,
Satisfaction social 76 70	0 , , ,		
support (yes) (%)	11 \	, ,	, ,
	support (yes) (%)		

Mean (standard deviation), range, and percentages (%).

statistically significant differences between sociodemographic variables that reflect the nature of each specific age group. Thus, younger women tended to have fewer children than older ones (F(1.96) = 60.42, $p < 0.001, \eta^2 = 0.39$ ), had spent significantly more years in education  $(F(1.96) = 40.02, p < 0.001, \eta^2 = 0.29)$ , and were more likely to perform managerial or professional roles than older women  $(\chi^2(9) = 41.36, p < 0.001,$ V = 0.37).

In terms of medical data, the number of months since diagnosis for the overall sample ranged from 3-41 (mean = 15.04 (SD = 7.92), median = 13); T1/T2 were themost common stages of disease (42% and 38%, respectively). There were no statistically significant differences for medical variables between groups.

In the BC group, 22% of women had breast reconstruc-

tion, 40% had planned to do so, whereas 38% did not

contemplate it. A higher proportion of younger women had undergone reconstruction or had plans to do so compared with older ones (27.6% vs. 14.3%; 48.3% vs. 28.6%, respectively), whereas older women decided against reconstruction more often than younger women (57.1% vs. 24.1%) ( $\chi^2(2)=5.65$ , p=0.059,V=0.34). In the GC group, the most frequently affected organ was the uterus (58% vs. 42% ovarian).

With regard to social support, there was a significant effect of the type of cancer and an interaction effect between the age and type of cancer (F(1.96)=4.47, p=0.037,  $\eta$ 2=0.04). Thus, the older GC group had received significantly more social support than the older BC group, and the younger BC group more than the older BC group. Furthermore, a higher percentage of older women were satisfied with the social support received compared with younger women ( $\chi$ <sup>2</sup>(3)=9.64, p=0.022,V=0.31).

# Psychological distress

Age was found to have a significant main effect on PD variables but the type of cancer was not (Table 2). Thus, younger women showed significantly greater distress than older ones (p-values < 0.001), but there were no significant differences between breast and GC groups. Data also showed a significant interaction effect between age and type of cancer, indicating that older BC women had worse BI and more depression than their GC counterparts (p-values < 0.001), but no significant differences were found in these two variables between younger groups (p=0.711; p=0.171, respectively). Also, we found a marginally significant interaction for self-esteem (p=0.059), showing a similar pattern to the previous results: the older BC group had less self-esteem than the older GC group (p=0.067).

The correlation matrix (Table 3) showed that being younger, having fewer children, planning to have more children, having a higher educational level, having an

inactive occupational status, suffering post-adjuvant therapy side effects, and being dissatisfied with social support were associated with more PD. All PD measures were strongly interrelated (p-values < 0.001), showing a marked comorbidity between BID, lower self-esteem, high depression, and high anxiety.

Finally, in the multiple regression analysis (Table 4), the percentage of variance explained by the four prediction models ranged 19.4%–51.5%. The variables that jointly predict higher BID and depression included in the model were: being younger, inactive occupational status, and post-adjuvant therapy side effects. For lower self-esteem, the variables included were: being younger, post-adjuvant therapy side effects, and dissatisfaction with social support. And for higher anxiety, the sole variable included was post-adjuvant therapy side effects.

## **Discussion**

Overall, our data suggest that age plays a larger role than cancer type/surgery, given that it was found to have a significant main effect on all PD domains, whereas the type of cancer did not. As expected, younger women had greater PD than older ones, regardless of the type of cancer they had or surgery they underwent. These findings are consistent with previous research showing a consistent pattern of younger women having greater psychological morbidity and poorer quality of life than older women in both, BC [12,25,29,31,39] and GC [21,23,24,40,52]. Nevertheless, these age-related differences are not surprising, if one considers that younger patients must suddenly face a series of anomalous changes not connected to their current stage in life, such as the loss of fertility, menopause symptoms, and problems with relationships, sexual functioning, and BI [31,36]. These factors may explain the greater distress experienced by younger rather than older women [25,52].

Table 2. Psychological distress

	Breast cancer			Gynecological cancer				
	Total (n = 50)	Younger (n = 29)	Older (n=21)	Total (n = 50)	Younger (n = 28)	Older (n = 22)	Statistical	
Body image disturbance Self-esteem	17.50 (10.63) 24.90 (8.95)	22.07 (8.16) <sup>a</sup> 22.34 (8.83) <sup>a</sup>	11.19 (10.57) <sup>a,c</sup> 28.43 (8.03) <sup>a</sup>	13.56 (11.30) 26.14 (10.53)	21.11 (8.34) <sup>b</sup> 20.57 (10.23) <sup>b</sup>	3.95 (6.00) <sup>b,c</sup> 33.23 (5.49) <sup>b</sup>	Kruskal–Wallis(3) = 47.385 $p < 0.001$ $F^{1}(1.96) = 0.776 p = 0.380$ $F^{2}(1.96) = 29.794 p < 0.001$ $F^{3}(1.96) = 3.664 p = 0.059$	
Depression	22.88 (16.57)	29.28 (15.90) <sup>a</sup>	14.05 (13.34) <sup>a,c</sup>	22.64 (19.90)	34.64 (17.11) <sup>b</sup>	7.36 (10.52) <sup>b,c</sup>	. ` /	
Anxiety	18.86 (13.01)	23.52 (12.89) <sup>a</sup>	12.43 (10.35) <sup>a</sup>	15.94 (13.61)	19.93 (15.11) <sup>b</sup>	10.86 (9.50) <sup>b</sup>	$F^{1}(1.96) = 0.824 p = 0.366$ $F^{2}(1.96) = 14.453 p < 0.001$ $F^{3}(1.96) = 0.370 p = 0.544$	

Mean (standard deviation).

F<sup>1</sup>, type of cancer; F<sup>2</sup>, age; F<sup>3</sup>, interaction.

<sup>&</sup>lt;sup>a</sup>Significant differences between younger and older BC groups.

bSignificant differences between younger and older GC groups.

<sup>&</sup>lt;sup>c</sup>Significant differences between older BC and older GC groups.

Table 3. Correlations between psychological distress and sample characteristics

	Body image disturbance	Self-esteem	Depression	Anxiety	
Age	-0.643**	0.440**	-0.559**	-0.327**	
Marital status (with/without partner)	-0.011	-0.060	0.056	0.086	
Children (number)	-0.524**	0.290**	-0.419**	-0.348**	
Planning more children (no/yes)	0.425**	-0.409**	0.516**	0.250*	
Education (years)	0.372**	-0.216*	0.295**	0.204*	
Occupational status (inactive/active)	0.458**	-0.290**	0.404**	0.283**	
Socioeconomic status <sup>a</sup> (low/medium/high)	0.114	-0.023	0.104	0.083	
Cancer (gynecological/breast)	0.178	-0.064	0.007	0.110	
Disease stage <sup>a</sup> (T1/T2/T3)	-0.118	0.085	-0.043	-0.110	
Time since diagnosis	-0.013	0.113	-0.019	-0.148	
Side effects post-adjuvant therapy	0.336**	-0.351**	0.481**	0.334**	
Menopausal complaints	0.127	-0.141	0.087	0.106	
Disease recurrence (no/yes)	0.095	-0.002	0.122	0.018	
Social support (amount)	-0.038	0.105	-0.047	0.011	
Satisfaction social support (no/yes)	-0.242	0.349**	-0.250*	-0.192	
Self-esteem	-0.733**				
Depression	0.832**	-0.832**			
Anxiety	0.564**	-0.473**	0.491**		

<sup>&</sup>lt;sup>a</sup>Spearman correlation.

Table 4. Multiple regression for psychological distress variables

	Adjusted R <sup>2</sup>	F	B(95% CI)	SE	Beta	sr2
Body image disturbance	51.5%	18.34				
Constant			24.27 (13.39-35.15)	5.48		
Age			-0.37 (-0.54-(-0.20))	0.84	-0.46***	-0.31
Occupational status			5.87 (2.48–9.26)	1.71	0.26**	0.24
Side effects post-adjuvant therapy			0.65 (-0.001-1.14)	0.33	0.15*	0.14
Self-esteem	28.9%	7.62				
Constant			15.55 (4.00-27.10)	5.82		
Age			0.26 (0.08–0.44)	0.09	0.37**	-0.25
Side effects post-adjuvant therapy			-0.84 (-1.54-(-0.15))	0.35	-0.21*	-0.21
Satisfaction with social support			5.35 (1.49-9.20)	1.94	0.25**	0.24
Depression	45.0%	14.35				
Constant			39.00 (19.89–58.11)	9.62		
Age			-0.58 (-0.87-(-0.29))	1.21	-0.44***	-0.29
Occupational status			6.43 (0.48–12.37)	2.99	1.18*	0.16
Side effects post-adjuvant therapy			2.39 (1.24-3.54)	0.58	0.32***	0.31
Anxiety	19.4%	4.93				
Constant			18.13 (1.27-34.98)	8.49		
Side effects post-adjuvant therapy			1.36 (0.34–2.37)	0.51	0.25**	0.24

Model adjusted for age, children, planning to have more children, education, occupational status, post-adjuvant therapy side effects, and satisfaction with social support. SE, standard error; sr<sup>2</sup>, squared semi-partial correlation.

Interestingly, our results also showed a significant interaction between age and type of cancer/surgery for BI and depression and a marginally significant interaction for self-esteem, indicating that older mastectomy women had worse BI, more depression, and lesser self-esteem than older hysterectomy/oophorectomy women. These

findings suggest that dealing with the loss of the breast can be a major challenge for older women than dealing with the loss of the uterus/ovaries. One possible explanation is that mastectomy produces bodily changes that are hard to ignore, as they are visible daily [36], whereas hysterectomy/oophorectomy does not create any visible body

<sup>\*</sup>p < 0.05.

<sup>\*\*</sup>p < 0.01.

<sup>\*</sup>p < 0.05.

<sup>\*\*</sup>p < 0.01.

<sup>.100.0 &</sup>gt; d\*\*\*

disfigurement [8]. Thus, mastectomy women are more likely to become self-conscious of their body and physical appearance and to experience problems with their BI compared with hysterectomy/oophorectomy women. In our study, the magnitude of BID score among older mastectomy patients was high compared with hysterectomy/oophorectomy patients and to the scores reported for several BC samples in other studies using the same measure scale [32,43,53], therefore suggesting that BI is a major issue for these women regardless of whether or not they have fewer concerns about BI than younger patients. Other researchers have found that BI is an important issue for older women who underwent mastectomy, indicating that prior assumptions about BI not being important for them may not always be true [54]. Similarly to other studies [38,55], our results showed that BID was strongly correlated with depressive symptoms and poor self-esteem, which would help to understand why women in the older mastectomy group present more depression and lower self-esteem than their GC counterparts.

Another key issue is the role of social support. Our findings showed that older BC group had received significantly less support than the older GC group; indeed, compared with the others, this group received the least amount of support. Given that social support has been widely acknowledged as a protective factor for PD and mental well-being [56–58] and that lower levels of social support have been associated with high levels of depression [59], it is reasonable to think that the lower support received could have contributed to increased psychological problems for these women. Our data do not confirm this assumption because we found no relationship between the amount of support received and PD measures. By contrast, satisfaction with social support was significantly associated with fewer BI problems, less depression, and better self-esteem, but there were no statistically significant differences between groups (older BC vs. older CG) in the proportion of women who were satisfied with the support received. Thus, it seems that neither the amount of support nor satisfaction with it can explain the differences found in depression and BI among older BC and older GC groups.

In the multiple regression analysis, few sociodemographic and medical factors were related to PD; inactive occupational status predicted more BID and depression, whereas satisfaction with social support was a predictor for better self-esteem; younger age and post-adjuvant therapy side effects were related to all PD domains, predicting poor outcomes. Several studies have shown that physical sequelae from cancer treatment affect adversely the quality of life [39], emotional state [21,23], self-esteem [60], and BI [61]. Thus, it appears that side effects from adjuvant therapy could be a major potential disadvantage for women in their daily life, which may

affect their psychological equilibrium, producing more distress. As mentioned before, and similarly to other studies [41], we found no relationship between the amount of perceived social support and PD measures; instead, a relationship was seen between satisfaction with social support and better self-esteem. This suggests that social support should fit the needs of the person in order to be beneficial for their psychological status [61]. Consequently, and given the association between negative self-esteem and depressive symptoms [59] and between higher self-esteem and mental well-being [56], health services should aim to meet the specific needs of women undergoing mastectomy and hysterectomy/oophorectomy in order to target unmet needs and provide quality services [58,62].

This study has several limitations. First, our sample may not be representative of the general population of women with BC or GC because of the incidental and relatively small sample recruited from a single hospital center. Second, the cross-sectional design used restricts the generalizability of our findings to similar groups of cancer survivors. Third, we have not been able to obtain reliable data about the overall response rate and characteristics of patients who refused to participate. This was due to the fact that eligible participants were approached by different oncologists during their routine clinical practice, and only some of them recorded how many accepted or declined the invitation to participate. Finally, we did not consider time since surgery or since completion of treatment; thus, it is not possible to know if these factors have influenced the results. Nevertheless, we believe that we have controlled this through the inclusion criteria required to participate in the study and the variable time since diagnosis, which showed no effect on any of the measures of PD. Likewise, other researchers have not found any relationship between time since diagnosis and different measures of distress or quality of life [21,31] or between time since the end of treatment and BID [36,39].

Despite these limitations, to our knowledge, this is the first report which compares the PD in women with BC or GC treated with radical surgery, considering the influence of age and other sociodemographic, medical, and social factors. Furthermore, our study shows some results worthy of consideration, as both mastectomy and hysterectomy/oophorectomy surgeries produce more distress in younger women compared with older women; mastectomy is associated with a higher BID and depression in older women (above 50 years old) than hysterectomy/oophorectomy; that suffering side effects from adjuvant treatments increases PD, whereas remaining occupationally active decreases depressive symptoms, and being satisfied with the social support received increases self-esteem. These findings have some

implications for clinical care. First, to improve the mental health status of BC or GC survivors, healthcare providers should pay more attention to the psychological effects of surgery and of adjuvant treatments in follow-up services. Second, oncology professionals should be more aware of the importance of BI concerns in older women with BC and offer them the same treatment options as they do to younger women, especially when taking into account that clinician preferences for mastectomy may be significantly influenced by increasing patient age [63]. Finally, younger women with BC or GC

may require specific interventions to prepare them to face the challenges of radical surgery and adjuvant treatments

# Acknowledgements

This study was supported by a public grant from 'Agencia Lain Entralgo' (Ministry of Health; Madrid, Spain). The authors thank Maria Die-Trill (University General Hospital 'Gregorio Marañón', Madrid, Spain) for her assistance during the data collection process.

### References

- American Cancer Society. Global cancer facts and figures. 2<sup>a</sup> Edition. 2011 Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-027766.pdf
- Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century a period analysis. *Lancet* 2002;360(9340):1131–1135.
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61(2):69–90.
- Cabanes A, Pérez-Gómez B, Aragonés N, Pollán M, López-Abente G. La situación del cáncer en España, 1975–2006. Instituto de Salud Carlos III. Madrid, 2009.
- Abasher SM. Sexual health issues in Sudanese women before and during hormonal treatment for breast cancer. *Psycho-Oncology* 2009;18(8):858–865.
- Dizon DS. Quality of life after breast cancer: survivorship and sexuality. *Breast J* 2009; 15(5):500–504.
- Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 2004;2004(32):57–71.
- Keskin G, Gumus AB. Turkish hysterectomy and mastectomy patients—depression, body image, sexual problems and spouse relationships. *Asian Pac J Cancer Prev* 2011; 12(2):425–432.
- McDowell ME, Occhipinti S, Ferguson M, Dunn J, Chambers SK. Predictors of change in unmet supportive care needs in cancer. *Psycho-Oncology* 2009;29(5):508–516.
- Lee MS, Love SB, Mitchell JB et al. Mastectomy or conservation for early breast cancer: psychological morbidity. Eur J Cancer 1992;28A(8/9):1340–1344.
- Fallowfield LJ, Hall A, Maguire GP, Baum M. Psychological outcomes of different treatment policies in women with early breast cancer outside of a clinical trial. *BMJ* 1990;301(6752):575–580.
- King MT, Kenny P, Shiell A, Hall J, Boyages J. Quality of life three months and one year after first treatment for early stage breast cancer: influence of treatment and patient characteristics. *Qual Life Res* 2000;9(7):789–800.

- Hopwood P, Maguire P. Body image problems in cancer patients. Br J Psychiatry 1988;153(Suppl. 2):47–50.
- Schover LR. The impact of breast cancer on sexuality, body image and intimate relationships. CA Cancer J Clin 1991;41(2): 112–120.
- Schover LR, Yetman RJ, Tuason LJ. Partial mastectomy and breast reconstruction. A comparison of their effects on psychosocial adjustment, body image and sexuality. Cancer 1995;75(1):54–64.
- Nano MT, Gill PG, Kollias J, Bochner MA, Malycha P, Winefield HR. Psychological impact and cosmetic outcome of surgical breast cancer strategies. ANZ J Surg 2005; 75(11):940–947.
- Al-Ghazal SK, Fallowfield L, Blamey RW. Comparison of psychological aspects and patient satisfaction following breast conserving surgery, simple mastectomy and breast reconstruction. *Eur J Cancer* 2000; 36(15):1938–1943.
- Yeo W, Kwan WH, Teo PM et al. Psychosocial impact of breast cancer surgeries in Chinese patients and their spouses. Psycho-Oncology 2004;13(2):132–139
- Mendonsa RD, Appaya P. Psychiatric morbidity in outpatients of gynecological oncology clinic in a tertiary care hospital. *Indian J Psychiatry* 2010;52(4):327–332.
- Andersen BL, Anderson B, de Prosse C. Controlled prospective longitudinal study of women with cancer: II. Psychological outcomes. *J Consult Clin Psychol* 1989; 57(6):696–697.
- 21. Bodurka-Bevers D, Basen-Engquist K, Carmack CL *et al.* Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. *Gynecol Oncol* 2000;**78**(3 Pt 1): 302–308.
- Urbaniec OA, Collins K, Denson LA, Whitford HS. Gynecological cancer survivors: assessment of psychological distress and unmet supportive care needs. *J Psycho-Oncology* 2011;29(5):534–551.
- Ell K, Sanchez K, Vourlekis B et al. Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. J Clin Oncol 2005;23(13):3052–3060.

- Linden W, Vodermaier A, MacKenzie R, Greig D. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. *J Affect Disord* 2012;**141**(2-3): 343–351.
- Wenzel LB, Fairclough DL, Brady MJ et al.
   Age related differences in the quality of life of breast carcinoma patients after treatment.
   Cancer 1999;86(9):1768–1774.
- 26. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: understanding women's healthrelated quality of life and sexual functioning. *J Clin Oncol* 1998;16(2):501–514.
- Cordova MJ, Andrykowski MA, Kenady DE, McGrath PC, Sloan DA, Redd WH. Frequency and correlates of posttraumaticstress-disorder-like symptoms after treatment for breast cancer. *J Clin Oncol* 1995; 63(6):981–986.
- Mor V, Allen S, Malin M. The psychosocial impact of cancer on older versus younger patients and their families. *Cancer* 1994; 74(7):2118–2127.
- Vinokur AD, Threatt BA, Vinokur-Kaplan D, Satariano WA. The process of recovery from breast cancer for younger and older patients. Changes during the first year. *Cancer* 1990;65(5):1242–1254.
- Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. Women. *Breast* Cancer Res 2007;9(3):R28.
- Avis NE, Crawford S, Manuel J. Quality of life among younger women with breast cancer. *J Clin Oncol* 2005;23(15):3322–3330.
- 32. Hopwood P, Haviland J, Mills J, Sumo G, M Bliss J, START Trial Management Group. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (standardisation of breast radiotherapy trial). *Breast* 2007; 16(3):241–251.
- Mertz BG, Bistrup PE, Johansen C et al. Psychological distress among women with newly diagnosed breast cancer. Eur J Oncol Nurs 2012;16(4):439–443.
- Piot-Ziegler C, Sassi ML, Raffoul W, Delaloye JF. Mastectomy, body deconstruction, and impact on identity: a qualitative

Copyright © 2013 John Wiley & Sons, Ltd.

Psycho-Oncology 23: 459-466 (2014)

- study. *Br J Health Psychol* 2010;**15**(3): 479–510.
- Caldwell R, Lagana L, Koopman C. Altered sexuality and body image after gynecological cancer treatment: how can psychologists help? *Prof Psychol Res Pr* 2010;41(6): 533–540.
- Avis NE, Crawford S, Manuel J. Psychosocial problems among younger women with breast cancer. *Psycho-Oncology* 2004;13(5):295–308.
- Buote VM, Wilson AE, Strahan EJ, Gazzola SB, Papps F. Setting the bar: divergent sociocultural norms for women's and men's ideal appearance in real-world contexts. *Body Image* 2011;8(4):322–334.
- White CA. Body image dimensions and cancer a heuristic cognitive behavioural model. *Psycho-Oncology* 2000;9(3):183–192.
- Ahn SH, Park BW, Noh DY et al. Healthrelated quality of life in disease-free survivors of breast cancer with the general population. Ann Oncol 2007;18(1):173–182.
- Miller BE, Pittman B, Case D, McQuellon RP. Quality of life after treatment for gynecologic malignancies a pilot study in an outpatient clinic. *Gynecol Oncol* 2002; 87(2):178–184.
- Manos D, Sebastián J, Bueno MJ, Mateos N, De la Torre A. Body image in relation to selfesteem in a sample of Spanish women with early-stage breast-cancer. *Psicooncología* 2005;2(1):103–116.
- 42. Tiggemann M. Body image across the adult life span: stability and change. *Body Image* 2004;**1**(1):29–41.
- 43. Hopwood P, Fletcher I, Lee A, Al Ghazal S. A body image scale for use with cancer patients. *Eur J Cancer* 2001;**37**(2):189–197.
- Rosenberg M. Society and the Adolescent Self-image. Princeton University Press: Princeton, NJ, 1965.

- Echeburua E. Evaluación y Tratamiento de la Fobia Social. Martínez Roca: Barcelona, 1995.
- Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck depression inventory: twenty-five years of evaluation. *Clin Psychol Rev* 1988;8(1):77–100.
- 47. Vázquez C, Sanz J. Fiabilidad y valores normativos de la versión española del inventario para la depresión de Beck de 1978. Clínica y Salud 1997;8(3):403–422.
- Beck AT, Steer RA. Beck Depression Inventory Manual. The Psychological Corporation: San Antonio, TX, 1993.
- Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring anxiety: psychometric properties. J Consult Clin Psychol 1988;56(6):893–897.
- Sanz J, Navarro ME. Propiedades psicométricas de una versión española del Inventario de Ansiedad de Beck (BAI) en estudiantes universitarios. Ansiedad y Estrés 2003;9(1):59–84.
- Statistical package for social sciences. Chicago, Illinois, US SPSS Inc., Chicago, IL, USA.
- Rannestad T. Factors related to quality of life in long-term survivors of gynecological cancer. Expert Rev Obstet Gynecol 2010; 5(1):105–113.
- 53. Moreira H, Silva S, Marques A, Canavarro MC. The Portuguese version of the Body Image Scale (BIS)—psychometric properties in a sample of breast cancer patients. *Eur J Oncol Nurs* 2010;14(2):111–118.
- 54. Figueiredo MI, Cullen J, Hwang YT, Rowland JH, Mandelblatt JS. Breast cancer treatment in older women: does getting what you want improve your long-term body image and mental health?. *J Clin Oncol* 2004; 22(19):4002–4009.

- Helms RL, O'Hea EL, Corso M. Body image issues in women with breast cancer. *Psychol Health Med* 2008;13(3):313–325.
- Bloom JR, Stewart SL, Johnston M, Banks P, Fobair P. Sources of support and the physical and mental well-being of young women with breast cancer. Soc Sci Med 2001;53(11):1513–1524.
- Rumsey N, Harcourt D. Body image and disfigurement: issues and interventions. *Body Image* 2004;1(1):83–97.
- 58. Weiss T, Weinberger MI, Holland J, Nelson C, Moadel A. Falling through the cracks: a review of psychological distress and psychosocial service needs in older black and Hispanic patients with cancer. *J Geriatr Oncol* 2012;3(2):163–173.
- 59. Schroevers MJ, Ranchor AV, Sanderman R. The role of social support and self-esteem in the presence and course of depressive symtoms: a comparison of cancer patients and individuals from the general population. Soc Sci Med 2003;57(2):375–385.
- Reitzes DC, Mutran E. Self and health: factors that encourage self-esteem and functional health. *J Gerontol B Psychol Sci Soc Sc* 2006;61(1):S44–S51.
- 61. Thoits PA. Conceptual, methodological, and theoretical problems in studying social support as a buffer against life stress. *J Health Soc Behav* 1982;**23**(2):145–159.
- Papadakos J, Bussière-Côté S, Abdelmutti N et al. Informational needs of gynecologic cancer survivors. Gynecol Oncol 2012; 124(3):452–457.
- 63. Caldon LJ, Walters SJ, Ratcliffe J, Reed MW. What influences clinicians' operative preferences for women with breast cancer? An application of the discrete choice experiment. *Eur J Cancer* 2007;43(11): 1662–1669.

Copyright © 2013 John Wiley & Sons, Ltd.

Psycho-Oncology 23: 459-466 (2014)